Fragment-based drug design (FBDD) has led to a revolution in contemporary drug discovery, facilitating a bottom-up approach to the identification and evolution of bioactive small molecules into viable ...

Metrion Biosciences ("Metrion"), the specialist preclinical contract research organization (CRO) and a global leader in ion channel services, today announced the launch of its validated, ...

A comprehensive introduction and guide to High-Throughput Screening (HTS) by Cytometry, featuring assays, application data, and more. Chapters on popular and emerging applications, including new ...

Explore the impact of drug discovery automation in 2026, addressing complexity and improving decision-making across ...

Comprehensive digital guide to high-throughput screening (HTS) by cytometry, featuring assays, application data, and more Introduction to HTS cytometry and the all-in-one software solution for data ...

Combined market-leading speed and 27 channel capacity enable maximum flexibility and data generation New fluidics and clog detection systems further simplify operation and reduce instrument downtime ...

A research team from the University of Hong Kong has developed a general computational protocol for phosphorescent platinum(II) complexes via high throughput virtual screening and Δ-learning ...

In this GEN webinar, our expert speakers will show how Nanoworx combines technical expertise with scalable workflows to support the seamless development of nanomedicines from early discovery and ...

BOSTON--(BUSINESS WIRE)--Alloy Therapeutics (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today that it is ...

Metrion Biosciences, today announced the launch of its validated, high-throughput NaV1.9 screening assay to advance discovery and development of novel pain therapeutics. Validated drug discovery assay ...